VANI
Vivani Medical, Inc.
Medical - Devices
Market Cap$72M
5Y Perf.-94.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
VANI vs BRNS
Revenue, margins, valuation, and 5-year total return — side by side.
BRNS
Barinthus Biotherapeutics plc
Biotechnology
Market Cap$27M
5Y Perf.-95.2%
VANI vs BRNS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VANI | BRNS |
|---|---|---|
| Industry | Medical - Devices | Biotechnology |
| Market Cap | $72M | $27M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-26M | $-52M |
| Total Debt | $19M | $11M |
| Cash & Equiv. | $18M | $70M |
VANI vs BRNS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VANI
BRNS
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Vivani Medical, Inc. (VANI) | 100 | 5.9 | -94.1% |
| Barinthus Biotherap… (BRNS) | 100 | 4.8 | -95.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VANI vs BRNS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VANI and BRNS are tied at the top with 2 categories each — the right choice depends on your priorities. Barinthus Biotherapeutics plc is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
VANI
Vivani Medical, Inc.
The Growth Play
VANI has the current edge in this matchup, primarily because of its strength in growth exposure.
- EPS growth 14.0%
- -11.5% revenue growth vs BRNS's -100.0%
- +18.6% vs BRNS's -32.3%
Best for: growth exposure
BRNS
Barinthus Biotherapeutics plc
The Income Pick
BRNS is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.28
- -95.2% 10Y total return vs VANI's -98.8%
- Lower volatility, beta 1.28, Low D/E 15.2%, current ratio 7.77x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VANI | -11.5% revenue growth vs BRNS's -100.0% |
| Stability / Safety | BRNS | Beta 1.28 vs VANI's 1.38, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | VANI | +18.6% vs BRNS's -32.3% |
| Efficiency (ROA) | BRNS | -48.8% ROA vs VANI's -103.9%, ROIC -174.5% vs -94.0% |
VANI vs BRNS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
VANI vs BRNS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBRNSLAGGINGVANI
VANIVivani Medical, Inc.
1leads
BRNSBarinthus Biotherapeu…
2leads
6 Total Categories
CATEGORYLEADERvs VANIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BRNS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BRNS6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
VANI5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BRNS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
VANI and BRNS operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | VANIVivani Medical, I… | BRNSBarinthus Biother… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$27M | -$36M |
| Net IncomeAfter-tax profit | -$26M | -$52M |
| Free Cash FlowCash after capex | -$25M | -$36M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | +71.4% |
BRNS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — VANI and BRNS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | VANIVivani Medical, I… | BRNSBarinthus Biother… |
|---|---|---|
| Market CapShares × price | $72M | $27M |
| Enterprise ValueMkt cap + debt − cash | $73M | -$32M |
| Trailing P/EPrice ÷ TTM EPS | -2.81x | -0.41x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 3.78x | 0.37x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — VANI and BRNS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
BRNS leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
BRNS delivers a -63.8% return on equity — every $100 of shareholder capital generates $-64 in annual profit, vs $-20 for VANI. BRNS carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to VANI's 1.10x.
| Metric | VANIVivani Medical, I… | BRNSBarinthus Biother… |
|---|---|---|
| ROE (TTM)Return on equity | -19.9% | -63.8% |
| ROA (TTM)Return on assets | -103.9% | -48.8% |
| ROICReturn on invested capital | -94.0% | -174.5% |
| ROCEReturn on capital employed | -65.2% | -46.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | 1.10x | 0.15x |
| Net DebtTotal debt minus cash | $961,000 | -$59M |
| Cash & Equiv.Liquid assets | $18M | $70M |
| Total DebtShort + long-term debt | $19M | $11M |
| Interest CoverageEBIT ÷ Interest expense | — | -1808.55x |
BRNS leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
VANI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VANI five years ago would be worth $727 today (with dividends reinvested), compared to $495 for BRNS. Over the past 12 months, VANI leads with a +18.6% total return vs BRNS's -32.3%. The 3-year compound annual growth rate (CAGR) favors VANI at -3.3% vs BRNS's -34.1% — a key indicator of consistent wealth creation.
| Metric | VANIVivani Medical, I… | BRNSBarinthus Biother… |
|---|---|---|
| YTD ReturnYear-to-date | -4.7% | -8.8% |
| 1-Year ReturnPast 12 months | +18.6% | -32.3% |
| 3-Year ReturnCumulative with dividends | -9.7% | -71.4% |
| 5-Year ReturnCumulative with dividends | -92.7% | -95.0% |
| 10-Year ReturnCumulative with dividends | -98.8% | -95.2% |
| CAGR (3Y)Annualised 3-year return | -3.3% | -34.1% |
VANI leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VANI and BRNS each lead in 1 of 2 comparable metrics.
Risk & Volatility
BRNS is the less volatile stock with a 1.28 beta — it tends to amplify market swings less than VANI's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VANI currently trades 63.0% from its 52-week high vs BRNS's 22.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VANIVivani Medical, I… | BRNSBarinthus Biother… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 1.28x |
| 52-Week HighHighest price in past year | $1.92 | $2.92 |
| 52-Week LowLowest price in past year | $0.92 | $0.51 |
| % of 52W HighCurrent price vs 52-week peak | +63.0% | +22.9% |
| RSI (14)Momentum oscillator 0–100 | 49.2 | 54.9 |
| Avg Volume (50D)Average daily shares traded | 235K | 25K |
Evenly matched — VANI and BRNS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | VANIVivani Medical, I… | BRNSBarinthus Biother… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | 2 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BRNS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VANI leads in 1 (Total Returns). 2 tied.
Best OverallBarinthus Biotherapeutics p… (BRNS)Leads 2 of 6 categories
Loading custom metrics...
VANI vs BRNS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is VANI or BRNS a better buy right now?
Analysts rate Vivani Medical, Inc.
(VANI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VANI or BRNS?
Over the past 5 years, Vivani Medical, Inc.
(VANI) delivered a total return of -92. 7%, compared to -95. 0% for Barinthus Biotherapeutics plc (BRNS). Over 10 years, the gap is even starker: BRNS returned -95. 2% versus VANI's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VANI or BRNS?
By beta (market sensitivity over 5 years), Barinthus Biotherapeutics plc (BRNS) is the lower-risk stock at 1.
28β versus Vivani Medical, Inc. 's 1. 38β — meaning VANI is approximately 8% more volatile than BRNS relative to the S&P 500. On balance sheet safety, Barinthus Biotherapeutics plc (BRNS) carries a lower debt/equity ratio of 15% versus 110% for Vivani Medical, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — VANI or BRNS?
On earnings-per-share growth, the picture is similar: Vivani Medical, Inc.
grew EPS 14. 0% year-over-year, compared to -5. 8% for Barinthus Biotherapeutics plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VANI or BRNS?
Vivani Medical, Inc.
(VANI) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Barinthus Biotherapeutics plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VANI leads at 0. 0% versus 0. 0% for BRNS. At the gross margin level — before operating expenses — VANI leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VANI or BRNS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VANI or BRNS better for a retirement portfolio?
For long-horizon retirement investors, Barinthus Biotherapeutics plc (BRNS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
28)). Both have compounded well over 10 years (BRNS: -95. 2%, VANI: -98. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VANI and BRNS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.